

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

| | |
|--|---|
| SUBMISSION TYPE: | NEW ASSIGNMENT |
| NATURE OF CONVEYANCE: | ASSIGNMENT |
| CONVEYING PARTY DATA | |
| Name | Execution Date |
| ASCENDIS PHARMA A/S | 07/02/2013 |
| RECEIVING PARTY DATA | |
| Name: | ASCENDIS PHARMA GROWTH DISORDERS DIVISION A/S |
| Street Address: | TUBORG BOULEVARD 12 |
| City: | HELLERUP |
| State/Country: | DENMARK |
| Postal Code: | 2900 |
| PROPERTY NUMBERS Total: 1 | |
| Property Type | Number |
| Application Number: | 13515621 |
| CORRESPONDENCE DATA | |
| Fax Number: | (212)588-0500 |
| <i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i> | |
| Email: | dgamache@flhlaw.com |
| Correspondent Name: | FROMMER LAWRENCE & HAUG LLP |
| Address Line 1: | 745 FIFTH AVENUE |
| Address Line 4: | NEW YORK, NEW YORK 10151 |
| ATTORNEY DOCKET NUMBER: | 514453-3980 |
| NAME OF SUBMITTER: | DANIELLE GAMACHE |
| Signature: | /Danielle Gamache/ |
| Date: | 10/04/2013 |
| Total Attachments: 2 source=01341110#page1.tif source=01341110#page2.tif | |

CH \$40.00 13515621

PATENT

Declaration of Assignment

for Patents, Utility Model Rights and their applications

We the undersigned owner
of the following protective rights/applications:

European patent application no. 09179335.6;
International patent application no. PCT/EP2010/069710, published as
WO2011/073234A;
Australian patent application no. 2010332958;
Brazilian patent application no. 112012014721-8;
Canadian patent application no. 2 783 296;
Chinese patent application no. 201080057256.6, published as CN102711733A;
Hong Kong patent application no. 13104018.5;
European patent application no. 10790843.6, published as EP2512450;
Israeli patent application no. 219981;
Indian patent application no. 5200/CHENP/2012;
Japanese patent application no. 2012-543703, published as JP 2013-513647;
Mexican patent application no. MX/a/2012/006541;
Russian patent application no. 2012129674;
Singaporean patent application no. 201204304-8;
United States patent application no. 13/515621, published as 2012-0322721-A1; and
South African patent 2012/04334;

herewith assign those with all rights and duties, including the right to priority, to

Ascendis Pharma Growth Disorders Division A/S
Tuborg Boulevard 12
2900 Hellerup
Denmark

and agree that the assignment is recorded in the respective Patent Office.

Ascendis Pharma A/S
Tuborg Boulevard 12
2900 Hellerup
Denmark

Signature of the assignor

Jan Møller Mikkelsen
(in his capacity as Chief Executive Officer of Ascendis Pharma A/S)

Michael Wolff Jensen
(in his capacity as Chairman of Ascendis Pharma A/S)

Place/Date: Hellerup 02/07/2013

Place/Date: Hellerup 02/07/2013

Declaration of Acceptance

We hereby agree to the afore-mentioned assignment and apply for recording of the assignment in the registers of the Patent Office.

Ascendis Pharma Growth Disorders Division A/S
Tuborg Boulevard 12
2900 Hellerup
Denmark

Signature of assignee

Jan Møller Mikkelsen
(in his capacity as Chief Executive Officer of Ascendis Pharma Growth Disorders Division A/S)

Michael Wolff Jensen
(in his capacity as Chairman of Ascendis Pharma Growth Disorders Division A/S)

Place/Date: Hellerup 02/07/2013

Place/Date: Hellerup 02/07/2013